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Abstract

To identify genetic variants associated with diabetic retinopathy (DR), we performed a large, multiethnic genome-wide association study (GWAS). Discovery included eight European cohorts (n = 3,246) and seven African American cohorts (n = 2,611). We meta-analyzed across cohorts using inverse-variance weighting, with and without liability threshold modeling of glycemic control and duration of diabetes. Variants with a P value < 1 X 10-5 were investigated in replication cohorts that included 18,545 Europeans, 16,453 Asians and 2,710 Hispanics.  After correction for multiple testing, the C allele of rs142293996 in an intron of nuclear VCP-like (NVL) was associated with DR in European discovery cohorts (P = 2.1 x 10-9), but did not reach genome-wide significance after meta-analysis with replication cohorts. We applied the Disease Association Protein-Protein Link Evaluator (DAPPLE) to our discovery results to test for evidence of risk being spread across underlying molecular pathways. One protein-protein interaction network built from genes in regions associated with proliferative DR (PDR) was found to have significant connectivity (P=0.0009) and corroborated with gene set enrichment analyses.  These findings suggest that genetic variation in NVL, as well as variation within a protein-protein interaction network that includes genes implicated in inflammation, may influence risk for DR.


Diabetic retinopathy (DR) is a leading cause of blindness. ADDIN EN.CITE (1) Established risk factors include longer duration of diabetes (DoD) and poor glycemic control.(2)  Genetic factors are also implicated, with heritability of 52% for proliferative diabetic retinopathy (PDR). ADDIN EN.CITE (3, 4)  Several candidate gene and genome-wide association studies (GWAS) have been conducted. ADDIN EN.CITE (5-11) While several polymorphisms have been suggested to be associated with DR, few have been convincingly replicated. ADDIN EN.CITE (10, 12-15)

There are several reasons why studies have not yielded consistent findings.  The genetic effects are likely modest and identification requires large sample sizes. Previous studies have not consistently accounted for the strongest two covariates, DoD and glycemic control. Liability threshold (LT) modeling is one way to incorporate these covariates while also increasing statistical power. ADDIN EN.CITE (16)  Finally, previous genetic studies have largely examined individual variants.  Techniques that examine top GWAS findings collectively for variants that cluster in biological networks based on known protein-protein interactions have the potential to identify variants where there is insufficient power to detect their individual effects.

The purpose of this study was to identify genetic variants associated with DR by (1) assembling a large sample size through inclusion of multiple ethnicities, (2) incorporating DoD and glycemic control via LT modeling and (3) collectively examining variants that cluster in biological networks.



Research Design and Methods

All studies conformed to the Declaration of Helsinki tenets and were Health Insurance Portability and Accountability Act (HIPAA) compliant. Written informed consent was obtained from all participants.  Institutional Review Board /Ethics Committee approval was obtained by each individual study. 

Discovery Sample Description
The discovery sample, encompassing seven African American and eight European cohorts, arose from a consortium of 11 DR studies for a total of 3246 Europeans and 2611 African Americans.  ADDIN EN.CITE (6-8, 12, 13, 17, 18)  Inclusion criteria for the discovery stage were (1) type 2 diabetes and (2) European or African American ethnicity. Type 2 diabetes was defined as a fasting plasma glucose (FPG)  ≥ 126 mg/dL (7.0 mmol/L) or a hemoglobin A1C (HbA1C) ≥ 6.5% (48 mmol/mol) (19) with onset of the diabetes after age 30 years.  Table 1 summarizes the DR phenotyping protocols and covariates by discovery cohort. Phenotyping protocols have been previously described  ADDIN EN.CITE (4, 20-29) and additional details are in the Supplemental Materials. 

DR Case-Control Definitions
The analysis plan pre-specified four DR case-control definitions with varying Early Treatment Diabetic Retinopathy Study (ETDRS) score thresholds for cases and controls (Table 2).(30)  The primary case-control definition compared any DR to no DR (ETDRS ≥ 14 vs. ETDRS < 14, henceforth referred to as the any DR analysis).  There were three secondary case-control definitions.  The first compared patients with PDR to those without PDR (ETDRS ≥ 60 vs. ETDRS < 60, henceforth the PDR analysis).  The second compared those with non-proliferative DR (NPDR) or worse to those without DR (ETDRS ≥ 30 vs. ETDRS < 14, henceforth the NPDR analysis).  The third compared those with PDR to those without DR (ETDRS ≥ 60 vs. ETDRS < 14, henceforth the extremes of DR analysis).  The rationale for four definitions is in the Supplemental Materials.  Table 1 shows the available samples by cohort and ETDRS score thresholds. Supplemental Table 1 summarizes the mean values for glycemic control and DoD.

Statistical Analyses
The genotyping platforms and the numbers of single nucleotide polymorphisms (SNPs) genotyped are summarized in Supplemental Table 2. Details about quality control, imputation, and data filtering are in the Supplemental Materials. Supplemental Figure 1 provides a flow chart of the discovery and replication analyses.  For the four main case-control definition analyses, we performed each of the analyses (1) without incorporating DoD and glycemic control using EIGENSOFT  ADDIN EN.CITE (16, 31) and (2) with LT modeling of DoD and glycemic control using LTSCORE. ADDIN EN.CITE (16)   LT modeling details are in the Supplemental Materials.  Both the EIGENSOFT and LTSCORE tests were implemented in LTSOFT version 2.0 ( (​​)see Web Resources in Supplemental Material). For the discovery analyses, we ran principal components (PC) analysis with EIGENSTRAT using only typed SNPs and five PCs, separately by ethnicity and case-control definition.(32)  We computed association analyses for each of the seven African American and eight European cohorts separately and then meta-analyzed by ethnicity. Meta-analysis was performed using inverse-variance weighting, accounting for both effective sample size (defined as 4/[1/Ncase + 1/Ncontrol]) and allele frequency. ADDIN EN.CITE (33)  We also performed multiethnic (Europeans and African Americans together) meta-analyses for the any DR and PDR analyses using inverse-variance weighting and a sensitivity analysis of the any DR meta-analyses in African Americans and Europeans (see Supplemental Materials). Because we included rare variants in this GWAS, we also tested the robustness of the top associations (P < 5 × 10–8) by performing two additional tests: (1) a Fisher’s exact test on cases or controls aggregated across all cohorts tested per variant and on each cohort separately and (2) an inverse variance-weighted meta-analysis across cohorts using the natural logarithm of the odds ratio as the effect size (34) without adjusting for covariates.

P-value thresholds for genome-wide significance
The P-value thresholds for genome-wide significance were based on empirically-determined thresholds for different ancestral populations that account for the GWAS multiple testing burden, as well as population-specific linkage disequilibrium (LD) patterns (35):

(1)	P < 3.24 X 10-8 for SNPs ascertained in African ancestry populations
(2)	P < 5.0 X 10-8 for SNPs ascertained in European ancestry populations
(3)	P < 3.24 X 10-8 for SNPs ascertained in multiethnic meta-analyses  

We further corrected these thresholds for additional multiple testing from examination of four case-control definitions, each with and without covariate incorporation, for eight tests total.  This yielded the following P-value thresholds for our study:

(4)	P < 3.75 X 10-9 for SNPs ascertained in African ancestry populations 
(5)	P < 6.25 X 10-9 for SNPs ascertained in European ancestry populations
(6)	P < 3.75 X 10-9 for SNPs ascertained in multiethnic meta-analyses

We note that correction for eight tests is conservative, because the case-control definitions are not completely independent.  We did not apply further multiple testing correction for the different ancestries analyzed. 

Replication Meta-Analysis
Eight European, eight Asian and four Hispanic replications cohorts provided summary statistics on SNPs with P < 1 X 10-5 in the discovery analyses (Table 3). Their phenotyping/genotyping protocols have been previously described and details are in the Supplemental Material.  ADDIN EN.CITE (6-8, 12, 13, 17, 18)  The rationale for including additional ethnicities in the replication phase is that high trans-ethnic genetic correlations have been documented for type 2 diabetes and other traits/diseases and support the use of multiethnic studies to increase sample size. ADDIN EN.CITE (36) Supplemental Table 3 summarizes the replication cohorts’ mean values for HbA1C, FPG, and DoD. Replication was in silico with existing genotyping. LT modeling was not applied to the replication cohort analyses.  The replication cohorts used standard covariate adjustment in their regression models. Replication meta-analysis was also performed using inverse-variance weighting – first individually by each ethnicity (Europeans, Hispanics, Asians) followed by all cohorts combined.  Replicated genome-wide significance had to meet the aforementioned thresholds after meta-analysis of the discovery and replication results.  



Protein-Protein Interaction Analysis of Top GWAS Loci
To identify significantly-enriched protein networks among the loci with the highest statistical evidence for association to DR, we applied the Disease Association Protein-Protein Link Evaluator (DAPPLE) to our discovery GWAS.(37) It has been shown that top associated loci, despite not being genome-wide significant, tend to cluster in biological networks. ADDIN EN.CITE (37, 38) For this reason, we examined the top 1000 loci from the discovery GWAS in the two mono-ethnic analyses (European and African American) and for each of the four case-control definitions analyses which incorporated DoD and glycemic control (eight network analyses in total). Our threshold for significance was therefore P < 0.00625 (0.05 corrected for eight tests). We used the publically available version of DAPPLE, and the protocol is outlined in the Supplemental Materials. This methodology has been used successfully with previous GWAS to identify protein networks with biological relevance. ADDIN EN.CITE (37-39)

Gene Set Enrichment Analysis of DAPPLE significant genes
To further support the protein-protein interaction results from the DAPPLE analysis, we applied gene set enrichment analysis (GSEA) using MAGENTA (Meta-Analysis Gene-Set Enrichment of variaNT Associations)  ADDIN EN.CITE (40) to the set of genes significantly enriched for protein-protein interactions in the DAPPLE analysis (details in Supplemental Materials).  

Type 2 diabetes and Associated Glycemic Traits Loci
To understand to what extent genetic determination of DR might reflect enrichment for type 2 diabetes or glycemic control genes, we computed a correlation between case status in the any DR analysis and the sum of the beta*risk allele (for quantitative glycemic traits) or logOR*risk allele (for type 2 diabetes) of the trait-associated SNPs for each cohort and each trait (see Supplemental Materials for details). 

Results

Discovery Meta-Analysis
Supplemental Figure 2 shows the PC analysis. We observed little inflation in the association statistic distribution (Supplemental Figure 3), indicating no significant population stratification as a confounder. Supplemental Figure 4 shows the Manhattan plots for the any DR analyses. Supplemental Tables 4 - 25 show the top 10 SNPs for independent loci with the lowest P values for each discovery analysis, including the sensitivity analyses (full results available at https://www.ncbi.nlm.nih.gov/gap).  

Table 4 shows SNPs that met the traditional nominal threshold for genome wide significance of P < 5 X 10–8 from the discovery analyses. All of the SNPs in Table 4 were either from the PDR or extremes of DR analyses; Figure 1 shows the QQ and Manhattan plots for the PDR and extremes of DR analyses. The results for the associations in Table 4 are shown for each cohort separately in Supplemental Table 26. Results for these SNPs after meta-analysis with replication samples both combined and separated by ethnicity are shown in Table 5 and Supplemental Table 27, respectively.  

Genome-Wide Significant Finding from the Discovery Analyses in NVL Gene
Using the corrected significance thresholds, only one SNP in the discovery meta-analyses met genome-wide significance: rs142293996 for the extremes of DR analysis incorporating DoD and glycemic control in Europeans (P = 2.1 X 10-9). The association was not significant without adjusting for covariates based on a Fisher’s exact test (Supplemental Table 28). This is an intronic variant in the  nuclear VCP-like (NVL) gene which encodes a member of the AAA (ATPases associated with diverse cellular activities) superfamily.(41)  The NVL gene is widely expressed in vivo with highest expression in retina (https://www.proteinatlas.org/ENSG00000143748- NVL/tissue#top (​https:​/​​/​www.proteinatlas.org​/​ENSG00000143748- NVL​/​tissue#top​)). 

We tested whether this association was a significant cis-expression quantitative trait locus (eQTL) in the Genotype-Tissue Expression (GTEx) Project release v7 (see Supplemental Materials for eQTL analysis details). This variant, rs142293996, lies in the 22nd intron of NVL and is in LD (r2=0.62) with variant rs41271487 in the 24th intron of NVL. Rs41271487 is a significant eQTL (P = 6.4 X 10-6, effect size=1.27) in the GTEx spinal cord cervical c-1 tissue, targeting calpain 2 (CAPN2), a calcium-activated neutral protease (Supplemental Figure 5). Common variants in the intron or regulatory region of CAPN2, 527-576 kb upstream of the DR association, are associated with variation in serum alpha-carotene levels (42), a vitamin A precursor required for sight, supporting a functional role for this gene. Based on the eQTL analysis, increased expression of CAPN2 is associated with decreased risk of DR (Supplemental Figure 6).  CAPN2 is expressed in the retina (https://www.proteinatlas.org/ENSG00000162909-CAPN2/tissue (​https:​/​​/​www.proteinatlas.org​/​ENSG00000162909-CAPN2​/​tissue​)).   

When examined in the replication analyses (which included a more diverse population), the direction of effect in the replication cohorts for rs142293996 was the same but the meta-analysis P-value was not genome-wide significant (P = 4.10 X 10-6).  


Top Finding from the African American Discovery Analyses
In African Americans, the SNP with the lowest P value was rs115523882 from the PDR analysis (P = 5.37 X 10-9). This was short of the 3.75 x 10-9 threshold for significance in African Americans.  We could not reproduce this finding in the replication cohorts. This variant is located near the GOLIM4 gene, which helps process proteins and mediates protein transport. The SNP rs115523882 specifically changes a motif which is a binding site for Nlx3, a transcription factor in blood, suggesting it plays a regulatory role. This variant is mainly present in people of African ancestry [minor allele frequency (MAF) = 0.0393] and not common in other ethnic groups, suggesting we may have had insufficient power to replicate it.

Of note, there was one SNP, rs184340784, suggestively associated with DR (P = 3.52 X 10-8) in the extremes of DR analysis without covariates in African Americans that was not present in our replication cohorts (due to low MAF) and thus could not be replicated. Neither rs115523882 nor rs184340784 were analyzed for eQTL activity in GTEx due to their low MAF (MAF<0.01 in GTEx tissues).

Table 6 and Supplemental Table 29 show the discovery variants with P < 1 X 10-5 that achieved a nominal P < 0.05 in the complete replication sample or in one of the replication ethnicities, respectively, and had the same direction as the discovery samples.  None of these variants achieved genome-wide significance after discovery and replication meta-analysis, as defined above.

DAPPLE Results Protein-Protein Interactions
One protein network from the African American PDR analysis was significant (P=0.0009) for average binding degree within the network (Figure 2). The aforementioned top ranked SNP (rs115523882) could not be included in the DAPPLE analysis since its nearby gene (GOLIM4) is not in the protein database. The significant protein network includes genes with primary roles in inflammation including IFNG, IL22RA1, CFH and SELL. INFG encodes INF-γ which is highly expressed in ocular tissues from PDR patients. ADDIN EN.CITE (43) IL22RA1 encodes the IL-22 receptor and CFH encodes complement factor H; both proteins are suspected to play a role in PDR. ADDIN EN.CITE (44, 45) SELL encodes L-selectin, which is expressed at higher levels in lymphocytes from DR patients and associated with increased endothelial adhesion.(46) We did not identify any statistically significant protein networks for any of the other case-control definitions in African Americans or in Europeans.

MAGENTA Confirmation of DAPPLE Results
We examined the 41 genes in the significant network identified by the DAPPLE analysis via GSEA using MAGENTA.  The genes showed a significant (16.5-fold) enrichment of low association P-values in the African American PDR analysis (P < 1 X 10-6; Supplemental Figure 7 and Supplemental Table 30) and to a lesser extent in African American extremes of DR analysis (P =2 X 10-4; Supplemental Table 30), suggesting new DR associations of modest effects in African Americans (Supplemental Table 31). No significant gene set enrichment was found for the PDR and extremes of DR analyses in Europeans.

Loci Associated with Type 2 Diabetes and Glycemic Traits
The results of the correlation analysis between type 2 diabetes/glycemic trait-associated SNPs and DR case status are shown in Supplemental Table 32.  The Z-score for type 2 diabetes was +2.256 (P=0.024).  The correlation coefficient R was positive, indicating that a greater burden of SNPs that increase type 2 diabetes risk is correlated with having DR.  However, this Z-score was not significant after correcting for the six hypotheses (six traits) tested.  

Previously associated SNPs from Prior Studies
We extracted results from our discovery meta-analysis for the variants with the lowest association P-values from previously published DR GWAS or large candidate gene studies (Supplemental Table 33).  There were three variants that were nominally significant (P < 0.05) in our sample and had the same direction of effect as the previously published studies. Two of the variants—rs9896052 and rs6128—were from previous studies whose samples overlapped with some samples in our discovery meta-analysis, and therefore do not represent independent replication. ADDIN EN.CITE (10, 20) Variant rs1399634, originally found in Chinese patients (P = 2 x 10-6), was nominally significant in our European discovery cohort (P = 0.0124). Meta-analysis of the original study and our cohorts was performed using the same method as our discovery and replication meta-analyses and was short of genome-wide significance (OR = 1.47, P = 9.63 X 10-8).

Discussion
To our knowledge, this study represents the largest GWAS performed for DR. The discovery analysis included 3,246 Europeans and 2,611 African Americans. The replication analysis included 18,545 Europeans, 16,453 Asians, and 2,710 Hispanics.  Despite the relatively large sample size, we did not identify any individual variants that were associated at a genome-wide significant level after meta-analysis with multiethnic replication cohorts. However, among the most significant results in the African American PDR analysis, we did identify a statistically significant enrichment for a network of genes using DAPPLE which was corroborated by GSEA using MAGENTA.  

In the discovery meta-analyses, several variants from the PDR and extremes of DR analyses achieved nominal genome-wide significance of P < 5 X 10-8, but the only variant to achieve genome-wide significance after conservative multiple testing correction was rs142293996 in the European analysis for extremes of DR (P = 2.1 X 10-9).  It is notable that the variants with the most significant findings came from the two case-control definitions that have PDR as their case definition.  This is consistent with the fact that PDR has a higher heritability than overall DR. ADDIN EN.CITE (4)  While the most strongly associated variants in the discovery analyses (rs142293996 in NVL in Europeans and rs115523882 in GOLIM4 in African Americans) did not reach genome-wide significance with replication, it is still possible that they do play a role in DR pathogenesis.  NVL is highly expressed in the retina and the implicated variant is in LD with an eQTL acting on CAPN2 with functional implications in neural tissue.  The eQTL variant falls in a binding site of a transcription factor.(47)   The GOLIM4 variant also has a known regulatory role. 

We could not replicate the association with rs142293996 when we used the Fisher’s exact test, although the Fisher’s exact test did not allow for covariate incorporation.  There is potential for inflated false positive rate when standard association methods are applied to rare (e.g. MAF < 1%) variants in imbalanced (e.g. case fraction < 10%) case-control cohorts at modest sample sizes. ADDIN EN.CITE (48)  However, most cohorts in this study did not have case fraction <10%. Larger sample sizes will help determine the confidence in these top associations.

There was one variant suggestively associated in the extremes of DR discovery analysis in African Americans, rs184340784, which was not present in any replication datasets.  The T allele of this variant has a frequency of 0.0023 in African populations and 0 in European, East Asian, South Asian and Hispanic populations in the 1000 Genomes Phase 3 panel.  In the discovery analysis, the P = 3.52 X 10-8 was shy of the genome-wide significance threshold of 3.75 X 10-9 for variants discovered from the African ancestry analyses.  This variant is within an intronic region upstream of adherens junctions associated protein 1 (AJAP1) which has its highest expression in brain frontal cortex but is also expressed in the retina (https://www.proteinatlas.org/ENSG00000196581-AJAP1/tissue (​https:​/​​/​www.proteinatlas.org​/​ENSG00000196581-AJAP1​/​tissue​)).

In the DAPPLE analysis, we did find that the top signals for the PDR analyses in African Americans analysis were enriched for a biologic network. The advantage of DAPPLE is that it can identify a protein pathway which may not be evident solely from the primary individual variant GWAS.  The presence of an underlying network amongst the top loci suggests there are likely true associations within top findings that have yet to reach genome-wide significance due to limited power.  Multiple pathways including inflammatory pathways are implicated by this network. To confirm biological significance, these results will need to be followed up with functional in vitro studies.

The DAPPLE results were corroborated by the MAGENTA GSEA in the African American PDR and extremes of DR analyses. This network of genes, however, was not enriched for in Europeans. This could either be due to technical differences, e.g., the number of African American cases is ~3-fold larger than the number of European cases, or to biological reasons. For example, we found that the allele frequencies of the most significant variant per gene for 40% of these protein interacting genes are rare in Europeans (MAF < 0.2%), while common in African Americans (MAF > 1%), according to the Genome Aggregation Database (gnomAD, see Web Resources).

In the analysis between type 2 diabetes/glycemic trait SNPs and DR case status, only type 2 diabetes variants were significantly associated with DR prior to, but not after, multiple testing correction.  One previous study examined aggregate effects of 76 type 2 diabetes-associated variants in Asian patients. ADDIN EN.CITE (49) Participants in the top tertile of type 2 diabetes-risk score were 2.56-fold more likely to have DR compared with lowest tertile participants.  Our study’s result showed the same direction of effect as the prior study, with type 2 diabetes risk raising alleles increasing DR risk. The prior study did not examine glycemic traits.  Our inability to detect a correlation for glycemic traits may be due to the small amount of glycemic variance captured by these variants. In European patients, HbA1C SNPs explain approximately 5% of HbA1C variance. ADDIN EN.CITE (50)   
We were unable to replicate findings from previous studies. ADDIN EN.CITE (6-8, 12, 13, 17, 18) We did have the same direction of effect in our European discovery sample for rs1399634 (LRP2) which was initially reported in an Asian population.  However, the meta-analysis was shy of genome-wide significance. The overall lack of replication of previous reports’ findings is not surprising, given the heterogeneity in phenotyping, case-control definitions, ethnicities and analytic approaches, although we did try to match our case-control definitions to the original studies’ definitions.

There are many potential reasons why we were unable to identify replicable, significant associations from our discovery GWAS.  First, the genetic risk in DR development may be quite small in proportion to the non-genetic risk factors.  Therefore, even though we assembled the largest sample, it may not be sufficient to detect very modest effects.  There was heterogeneity between the discovery and replication cohorts that could contribute to inability to replicate.  The discovery cohort included individuals with type 2 diabetes while the replication cohorts included individuals with either type 1 or type 2 diabetes.  It is not known definitively whether genetic variants for DR differ between type 1 and type 2 diabetes. Clinically, DR phenotypes are similar in patients with type 1 and type 2 diabetes, so we hypothesize that at least some of the genetic risk is shared. However, we cannot be certain of this and heterogeneity of diabetes type might have contributed to lack of replication. The discovery cohort included individuals who were of either European or African American descent while the replication cohorts included individuals of European, Hispanic, or Asian descent. This heterogeneity could also have led to lack of replication. Europeans were represented in both the discovery and replication phases, but even our European discovery analysis has limited power. Power calculations show that our discovery GWAS for the any DR analysis in Europeans had 100% power to detect a variant with a MAF of 0.40 with a heterozygous genotypic relative risk (GRR) of 1.5 with a P-value < 5 X 10-8, whereas the power decreases to 5% for the same variant with GRR of 1.2. 

We attempted to harmonize the phenotypes as much as possible, but there were some limits to complete harmonization, particularly for cohorts with limited-field or no photography.  Misclassification of participants because of limited DR ascertainment could have biased the results to the null.  Although we did use LTSCORE modeling to account for DoD, we may have had some misclassification bias because we did not have a minimum DoD for controls – i.e. some controls could have developed DR with longer DoD - which would also bias our result towards the null.  We only had one HbA1c measure. Repeated HbA1c measures would reflect long-term glycemia more accurately.  

In summary, we have executed the largest GWAS of DR to date.  There were no genome-wide significant findings but analysis of protein-protein interaction networks point to possible candidate pathways for PDR in African Americans.  Future studies examining DR genetics would benefit from a greater international collaboration encompassing larger samples that would allow strict case-control definitions that define a minimal DoD without sacrificing power.  Furthermore, these studies should focus case definitions on the advanced forms of DR—PDR and diabetic macular edema (DME)—and incorporate more refined phenotyping, particularly optical coherence tomography for DME. Finally, whole genome sequencing might reveal a role for very rare variants, particularly for the DR phenotypic extremes.
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Table 1.  Studies included in the discovery sample
Study	Population	Diabetes Type	# of Eyes/# of Fields/Size of Fields Photographed		Diabetes Duration	Glycemic Control Measure	Cases(ETDRS ≥ 14)	Ctrls(ETDRS < 14)	Cases(ETDRS ≥ 60)	Ctrls(ETDRS < 60)	Cases(ETDRS ≥ 30)
AAPDR	AA	2	2/7/30 deg.		Y	HbA1C	274	56	255	75	261
AGES*	EUR	2	2/2/45 deg.		Y	HbA1C	85	222	3	304	8
ARIC	AA	2	1/1/45 deg.		Y	HbA1C	96	265	3	358	73
	EUR	2	1/1/45 deg.		Y	HbA1C	126	632	6	752	80
AUST	EUR	2	NA‡		Y	HbA1C	522	435	187	770	346
BMES	EUR	2	2/5/30 deg.		Y	FPG	124	208	1	331	37
CHS	AA	2	1/1/45 deg.		Y	FPG	19	35	4	50	14
	EUR	2	1/1/45 deg.		Y	FPG	26	119	4	141	16
FIND-Eye*	AA	2	2/2/45 deg.†		Y	HbA1C	330	167	264	233	303
	EUR	2	2/2/45 deg.†		Y	HbA1C	158	154	115	197	145
JHS	AA	2	2/7/30 deg.		Y	HbA1C	91	160	12	239	57
MESA	AA	2	2/2/45 deg.		Y	HbA1C	101	258	11	348	60
	EUR	2	2/2/45 deg.		Y	HbA1C	38	200	2	236	12
RISE/RIDE	EUR	2	2/7/30 deg.		Y	HbA1C	--	--	80	117	--
WFU	AA	2	NA‡		Y	HbA1C	--	--	548	211	--
TOTAL	AA	2	--		Y	Varies	911	941	1097	1514	768
TOTAL	EUR	2	--		Y	Varies	1079	1970	398	2848	644
Ctrls= Controls, AAPDR = African American Proliferative Diabetic Retinopathy Study, AGES = Age, Gene/Environment Susceptibility Study, ARIC = Atherosclerosis Risk In Communities Study, AUST= Australian Genetics of Diabetic Retinopathy Study, BMES = Blue Mountains Eye Study, CHS=Cardiovascular Health Study, FIND-Eye = Family Study of Nephropathy and Diabetes-Eye, JHS = Jackson Heart Study, MESA = Multiethnic Study of Atherosclerosis, RIDE/RISE= Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes, WFU=Wake Forest University, AA=African American, EUR = European, Illum=Illumina, Affy=Affymetrix, NA=not available, Y=information on diabetes duration is available, HbA1C=hemoglobin A1C, FPG=fasting plasma glucose, deg.= degrees, SNPs= single nucleotide polymorphisms, QC=quality control
* Cohorts without access to raw genotype information
† Not all FIND-Eye subjects had photographs but all participants had harmonization of exam and clinical data to an ETDRS score.
‡ The AUST study used examination by an ophthalmologist to ascertain diabetic retinopathy.  The WFU study used a questionnaire to ascertain diabetic retinopathy.


Table 2.  Four case-control definitions and the number of samples available for discovery for each definition.

	Controls		Cases
Analysis Name	Score	n AA	n EUR		Score	n AA	n EUR
Any DR (Primary Analysis)	< 14	941	1970		≥ 14	911	1079
PDR	< 60	1514	2848		≥ 60	1097	398
NPDR	< 14	941	1970		≥ 30	768	644
Extremes of DR	< 14	941	1970		≥ 60	1097	398
DR= diabetic retinopathy, PDR = proliferative diabetic retinopathy, NPDR = non-proliferative diabetic retinopathy, Score = ETDRS score range, AA = African American, EUR= European 


Table 3. Studies included in the replication meta-analyses

Cohort by Ancestry	Ethnicity/Nationality	DM Type	Any DR Analysis	PDR Analysis	NPDR Analysis	Extremes of DR Analysis
			Cases	Controls	Cases	Controls	Cases	Controls	Case	Controls
Asian
KSDR	Korean	2	1516	571	918	1167	1300	571	918	571
MESA 	Chinese	2	28	83	--	--	17	83	--	--
RIKEN	Japanese	2	5532	5565	--	--	2371	5565	--	--
SCES I	Chinese	2	75 	228 	--	--	--	--	--	--
SCES II	Chinese	2	27 	78 	--	--	--	--	--	--
SiMES	Malay	2	214 	557 	--	--	--	--	--	--
SINDI	Indian	2	315	669 	--	--	--	--	--	--
TUDR	Chinese	2	--	--	--	--	--	--	436 	559
European
DCCT/EDIC Primary cohort	North American	1	--	--	53 	598 	--	--	--	--
DCCT/EDICSecondary cohort, conventional treatment	North American	1	--	--	114 	209	--	--	--	--
DCCT/EDICSecondary cohort, intensive treatment	North American	1	--	--	42	288 	--	--	--	--
GENESIS/GENEDIAB	French	1	277 	999 	808 	468 	277	607 	277 	468
GoDARTS	Scottish		2506 	2412	574	4345	1381	2412	574	2412
GoKinD	North American	1	--	--	138	581	--	--	--	--
SUMMIT	European	1 and 2	5422	4302	--	--	--	--	--	--
WESDR	North American	1	--	--	309	294	--	--	--	--
Hispanic
GOLDR	Hispanics	2	298 	301	76	523	215	301	76	301
LALES	Hispanics	2	552	500	53	999	341	500	53	500
MESA	Hispanics	2	92	192	--	--	52	192	--	--
SCHS	Mexican Americans	2	528	247	103	672	406	247	103	247
Total			17382	16704	3188	10144	6360	10478	2437	5058
DM = diabetes mellitus, KSDR = Korean Study of Diabetic Retinopathy, MESA = Multiethnic Study of Atherosclerosis, RIKEN  = Rikagaku Kenkyusho - Institute of Physical and Chemical Research, SCES= Singapore Chinese Eye Study, SiMES = Singapore Malay Eye Study, SINDI = Singapore Indian Eye Study, DCCT/EDIC = Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications, GENESIS/GENEDIAB=Genetics nephropathy and sib pair study/Genetics, nephropathy, diabetes, GoDARTS =Genetics of Diabetes and Audit Research Tayside Study, GoKinD = Genetics of Kidneys in Diabetes, SUMMIT = Surrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools, WESDR = Wisconsin Epidemiologic Study of Diabetic Retinopathy, GOLDR = Genetics of Latino Diabetic Retinopathy, LALES = Los Angeles Latino Eye Study, SCHS = Starr County Health Studies, TUDR = Taiwan–US Diabetic Retinopathy Study

The SUMMIT cohort is a meta-analysis of three European studies: The Finnish Diabetic Nephropathy (FinnDiane) Study; Scania Diabetes Registry; and the Eurodiab study.





Table 4. Variants with P < 5 x 10-8 (traditional, nominal threshold for genome wide significance) in the discovery analyses 

							CASES	CONTROLS				
Case Control Definition	Population/LT Modeling	RSID	CHR	Position	Nearest Gene	REF	N	RAF	N	RAF	NEFF	P	OR	95% CI
PDR	AA/no	rs115523882	3	167876205	GOLIM4	A	1105	0.9823	1119	0.9611	1452	9.42 X 10-9	3.10	2.12, 4.53
PDR	AA/yes	rs115523882	3	167876205	GOLIM4	A	1105	0.9823	1119	0.9611	1452	5.37 X 10-9	3.10	2.14, 4.50
PDR	EUR/no	rs139205645	2	201949806	NDUFB3	T	309	0.9725	975	0.9959	907	3.93 X 10-8	0.13	0.06, 0.27
PDR	EUR/yes	rs17791488	17	26232732	NOS2/LYRM9	T	309	0.9871	975	0.9661	907	7.26 X 10-9	3.70	2.40, 5.71
Extremes of DR	AA/no	rs184340784	1	4589883	AJAP1	C	520	0.999	230	0.9784	603	3.52 X 10-8	NA	NA
Extremes of DR	EUR/yes	rs142293996	1	224448059	NVL	C	187	0.9947	435	0.9874	523	2.10 X 10-9	2.38	1.80, 3.14
Extremes of DR	EUR/yes	rs17706958	3	73837141	PDZRN3	T	308	0.8139	594	0.7332	797	3.04 X 10-8	1.58	1.35, 1.85
Extremes of DR	EUR/yes	rs80117617	2	40855125	SLC8A1	T	308	0.9838	594	0.9445	797	4.04 X 10-8	3.78	2.37, 6.02

LT= liability threshold, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, RAF= reference allele frequency, OR= odds ratio for reference allele, CI = confidence interval, AA= African Americans, EUR = European
















Table 5. Replication results for variants with P < 5 x 10-8 (traditional, nominal threshold for genome wide significance) in the discovery analysis 

Discovery Population/LT modeling	RSID	Nearest Gene	REF	DiscNEFF	DiscRAF	Disc P	DiscOR	AllRep NEFF	All RepRAF	AllRep OR	AllRep P	Disc + REP OR(95% CI)	Disc + Rep P
Variants identified in the PDR Discovery Analysis
AA/no	rs115523882	GOLIM4	A	1452	0.9721	9.42 X 10-9	3.10	571	0.9975	0.20	0.13	2.89 (1.97, 4.23)	8.51 X 10-8
AA/yes	rs115523882	GOLIM4	A	1452	0.9721	5.37 X 10-9	3.10	571	0.9975	0.20	0.18	2.89 (1.99, 4.20)	4.25 X 10-8
European/no	rs139205645	NDUFB3	T	907	0.9907	3.93 X 10-8	0.13	3431	0.9900	0.74	0.77	0.48 (0.29, 0.79)	0.004
European/yes	rs17791488	NOS2/LYRM9	T	907	0.9705	7.26 X 10-9	3.70	5883	0.9772	0.82	0.33	1.08 (0.98, 1.19)	0.12
Variants identified in the Extremes of DR Analysis
AA/no	rs184340784	AJAP1	C	603	0.0063	3.52 X 10-8	NA	*	*	*	*	--	--
European/yes	rs142293996	NVL	C	523	0.9895	2.10 X 10-9	2.38	1229	0.9910	3.23	0.16	2.91 (1.85, 4.57)	4.10 x 10-6
European/yes	rs17706958	PDZRN3	T	797	0.7615	3.04 X 10-8	1.58	4194	0.9828	1.28	0.02	1.39 (1.24, 1.56)	7.41 x 10-8
European/yes	rs80117617	SLC8A1	T	797	0.9598	4.04 X 10-8	3.78	3345	0.9726	1.29	0.24	1.71 (1.30, 2.25)	1.35 x 10-4

LT= liability threshold, RSID= rs identifier, CHR= chromosome, REF= reference allele, NEFF= Effective sample size, RAF= reference allele frequency in sample, ALL= all replication cohorts, OR= odds ratio for reference allele, CI = confidence interval, PDR = proliferative diabetic retinopathy, DR = diabetic retinopathy, AA= African Americans
* None of the replication cohorts were able to provide data for this SNP.








Table 6. Replication results for variants with nominal significance (P <0.05) in the combined (Hispanic, African American, and European cohorts) replication meta-analyses
Discovery Population/LT modeling	RSID	Nearest Gene	REF*	DISCEAF	DISC OR	DISC P	ALL REPOR	ALL REP P	DISC + REP OR	DISC + REP P
Variants identified in the Any DR Discovery Analysis
European (Sens)/no	rs1394919	PPEF2/NAAA	C	0.72	0.73	8.51 X 10-6	0.91	0.003	0.88	6.35 X 10-6
AA (Sens)/no	rs75360147	SLC28A3	T	0.93	2.08	7.07 X 10-6	2.65	0.009	2.17	2.29 X 10-7
European/no	rs1508244	HTR1E	A	0.98	0.33	3.74 X 10-6	0.92	0.01	0.90	0.002
ME/no	rs10432638	UBXN2A	C	0.73	0.78	2.60 X 10-6	0.93	0.01	0.89	7.74 X 10-6
EU/no	rs150775408	BC031225	C	0.95	1.97	7.24 X 10-6	1.27	0.04	1.46	2.54 X 10-5
AA/yes	rs143894698	GCM1	G	0.98	3.14	4.62 X 10-6	1.45	0.004	1.58	2.53 X 10-5
European/yes	rs13006587	ATAD2B	G	0.58	0.79	7.52 X 10-6	0.93	0.006	0.92	4.74 X 10-5
European/yes	rs73642012	PTPRD	C	0.91	0.67	9.58 X 10-6	0.90	0.02	0.87	8.67 X 10-5
Variants identified in the PDR Discovery Analysis
Europeans/no	rs139921826	PRSS35	G	0.98	0.33	7.92 X 10-6	0.66	0.03	0.62	0.0008
AA/yes	rs1414474	C1orf94	C	0.14	1.62	1.46 X 10-7	1.12	0.01	1.19	1.90 X 10-5
AA/yes	rs9998354	BTF3P13	T	0.44	0.73	8.74 X 10-6	0.92	0.04	0.87	0.0001
European/yes	rs142293996	NVL	C	0.99	1.83	1.14 X 10-6	2.40	0.04	2.29	0.0001
Variants identified in the NPDR Discovery Analysis
European/no	rs1508244	RN7SL643P	A	0.98	0.32	8.13 X 10-6	0.89	0.005	0.87	0.0005
European/no	rs7944308	KCNA4	G	0.42	0.71	7.76 X 10-7	0.94	0.02	0.90	5.80 X 10-5
Variants identified in the Extremes of DR Discovery Analysis
AA/no	rs74161190	TCERG1L	A	0.94	0.32	4.57 X 10-6	0.40	0.03	0.32	7.16 X 10-7
European/yes	rs17706958	PDZRN3	T	0.76	1.58	3.04 X 10-8	1.28	0.02	1.39	7.41 X 10-8
European/yes	rs10932347	CPS1	A	0.04	0.33	4.22 X 10-7	0.64	0.02	0.55	1.30 X 10-5
AA/yes	rs2690028	KAZN	C	0.32	0.62	4.52 X 10-6	0.80	0.03	0.74	1.72 X 10-5
European/yes	rs116972715	DSC3	C	0.99	2.60	2.48 X 10-6	3.62	0.03	3.29	1.59 X 10-5
European/yes	rs75167957	CTNNA2	C	0.99	3.26	3.36 X 10-6	9.77	0.04	6.34	5.83 X 10-6
AA/yes	rs6577631	LOC339862	G	0.86	0.53	3.45 X 10-6	0.89	0.04	0.84	0.0006
Sens= Sensitivity Analysis, ME = Multiethnic, AA = African American, DR = diabetic retinopathy, PDR = proliferative diabetic retinopathy, NPDR = non-proliferative diabetic retinopathy. * For insertions-deletion, the reference allele is shown first followed by the alternate allele


Figure Legends
Figure 1. Quantile-quantile and Manhattan plots for the PDR and extremes of DR discovery meta-analyses for: (A and B) PDR analysis in African American participants with liability threshold modeling of duration of diabetes and glycemic control; (C and D) PDR analysis in European participants with liability threshold modeling of duration of diabetes and glycemic control; (E and F) Extremes of DR analysis in African American participants with liability threshold modeling of duration of diabetes and glycemic control; and (G and H) Extremes of DR analysis in European participants with liability threshold modeling of duration of diabetes and glycemic control. The horizontal line in each of the Manhattan plots indicates the nominal threshold for genome-wide significance (P = 5 X 10-8).

Figure 2. Protein network from the African American proliferative diabetic retinopathy discovery analysis that was significant in the DAPPLE analysis.  This significant protein network includes genes with primary roles in inflammation (IFNG, IL22RA1, CFH, SELL), protein function/endoplasmic reticulum function (ADAMT30, ERP44, HSP90B1, SPON1, CNAX, WFS1), catabolic processing/metabolism (PPT1, ALDH1B1), gene expression/transcription factor activity (HNRNPH1, TAF4, POLR2E, TCEB1, COMMD1, PLAGL1, THRB, SIN3A), macromolecule transport (NUP153, NUP50), protein localization (SEC61B, SEC61A2), and DNA repair/cell cycle (RBBP8, ATM, EEF1E1). 






